|Brand name(s), other common name(s)||
|Drug type||CD38-directed cytolytic antibody (monoclonal antibody)|
|How the drug is given||Intravenously (IV)|
Indications and Usage
Isatuximab-irfc is FDA approved, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
Side effects needing medical attention
The most common adverse reactions were neutropenia, infusion-related reactions, pneumonia, upper respiratory tract infection, and diarrhea. The most common hematology laboratory abnormalities were anemia, neutropenia, abnormally low level of lymphocytes in the blood (lymphopenia), and thrombocytopenia.